Psychosomatic approach to disorders of the autonomic nervous system in general medical practice. O.O. Haystova. Neuronus № 2 (1), 2016

There was a parallel decrease in both autonomic symptomatic and affective symptomatology (anxiety and psycho-emotional lability) in monotherapy with mianserin. Multimodal drug mianserin (Miaser) at a dose of 10 mg/day is appropriate for monotherapy for somatoform vegetative dysfunction due to its effectiveness, safety and ease of use. Therefore, by the overall therapeutic effect, Miaser may be recommended for the treatment of disorders of the autonomic nervous system in general medical practice.

European reform vector in psychiatry. News of medicine and pharmacy № 5 (574), 2016

On April 14-15, 2016, a scientific and practical conference with international participation “From specialized psychiatric care to the mental health system” was held in Kyiv. As part of the conference program, a symposium was held on "The European Vector of Reform in Psychiatry and the Development of Forensic Psychiatry", dedicated to the issues of reorganization of psychiatric service in Ukraine, penitentiary psychiatry and forensic psychiatric practice. With the financial support of Farmlyga, it became possible to participate in a symposium of leading experts from Holland, Georgia and Lithuania. The experience of Lithuanian colleagues is extremely important as it exemplifies the successful reorganization of psychiatric service in post-Soviet countries.

Art that unites everyone. Health of Ukraine. Thematic number. December 2015

On November 5-6, 2015, at the Ukrainian House, was held a biennial entitled "Diagnosis: Artist" within the framework of the All-Ukrainian Project "Uniting All!" , where paintings of patients of psychiatric hospitals were displayed together with paintings by famous Ukrainian artists. The organizers of this project are the Ukrainian Research Institute of Social and Forensic Psychiatry and Addiction of the Ministry of Health of Ukraine and the Association of Psychiatrists of Ukraine. The event was supported by the Lithuanian pharmaceutical company Farmlyga and the Lithuanian Embassy. The purpose of the biennale was to demonstrate the creative potential of people with mental health disabilities and to draw public attention to the needs of these people and the importance of integrating them into society.

The effectiveness of Artrida® for lower back pain. O.H. Morozova, A.A. Yaroshevskiy, Ya.V. Lypynskaya

Summary. The article is devoted to the treatment of patients with chronic recurrent pain in the lower back. The data of a study of the clinical efficacy and safety of the drug Artrida ® are presented, the use of which in complex therapy at the time of exacerbation and the presence of topical pain syndrome allowed to reduce the time and dose of non-steroidal anti-inflammatory drugs, and also helped to improve the biomechanical parameters and functional ability of patients.

Arilentals - third generation antipsychotic. V.A. Manhubi. Neuronus. 2017.

Arilentals can safely be called a "third-generation" drug of atypical antipsychotics. The presence of a favourable endocrine safety profile and the absence of sedation when using aripiprazole favourably differentiates it from many members of the class of atypical antipsychotics.

The use of atypical neuroleptics in the practice of a family doctor. O.O. Haystova. Neuronus №8 (82), 2016

The use of quetiapine is appropriate for insomnia monotherapy in patients with anxiety and depressive disorders, chronic somatic diseases, including the elderly, at an initial dose of 25 mg. The presence of Quetixol (25 mg), a clinically bioequivalent original drug, makes it convenient and affordable to treat patients in this category.

Comparative analysis of atypical neuroleptics. O.S.Chaban. Neuronus № 10 (74), 2015

A considerable number of generic antipsychotic drugs are presented in the pharmaceutical market of Ukraine. However, the practitioner should pay attention to confirming their bioequivalence in volunteer-led research (clinical bioequivalence). Examples of products with proven bioequivalence in the Ukrainian market are Farmlyga products: Arilentals (aripiprazole), Risperon (risperidone), Quetixol (quetiapine) and Soleks (amisulpride).

Duloxetine in the treatment of chronic myofascial pain syndromes. O.H. Morozova, A.A. Yaroshevskiy. Neuronus. 2017

The efficacy of the Simoda drug in the treatment of chronic myofascial pain syndromes was revealed in our study. The administration of the drug at a dose of 30 mg made it possible to achieve faster control over pain and depressive manifestations, reduce the duration of NSAIDs, and in some cases to refuse them. The analgesic effect of the Simoda drug developed earlier (on the 7th day) than the antidepressant (on the 15th day). The analgesic effect of the Simoda drug developed earlier (on the 7th day) than the antidepressant (on the 15th day).

List of clinical referral sources according to the recommendations of the Ministry of Health of Ukraine.

World science is out of place and Ukrainians should not stay out of progress. The clinical guidelines we offer are constantly updated. Please use them. ”Ministry of Health of Ukraine, quoted from

Psychosomatic disorders in patients with allergodermatoses and their correction. E.F. Kutasevich. Dermatology and Venereology. No. 1 (83) 2019.

Stress and nervous-conflict situations in 35.44% of patients with allergodermatosis caused clinical manifestations of the disease. The use in the complex treatment of patients with allergic dermatitis antidepressant drug Miaser containing myanserine hydrochloride, reduces the itching intensity and its earlier relief and earlier onset of regression of psychosomatic disorders. Thus, Miasser (myanserine hydrochloride) has an effect not only on depressive anxiety disorders, mood and sleep disorders, but also on the presence and intensity of itching. Miasser containing myanserine hydrochloride at a dose of 10 mg per day per night should be used in the treatment of patients with allergodermatosis.